Details

Autor(en) / Beteiligte

• Home, Philip D
• Pocock, Stuart J
• Beck-Nielsen, Henning
• Gomis, Ramón
• Hanefeld, Markolf
• Jones, Nigel P
• Komajda, Michel
• McMurray, John J.V

Titel

Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis

Ist Teil von

• The New England journal of medicine, 2007-07, Vol.357 (1), p.28-38

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2007

Quelle

MEDLINE

Beschreibungen/Notizen

• Meta-analyses suggest that the thiazolidinedione rosiglitazone, used in the treatment of type 2 diabetes, may increase the risk of myocardial infarction and death from cardiovascular causes. This interim analysis of an ongoing noninferiority trial of rosiglitazone is inconclusive but does not exclude cardiotoxicity. Because patients with diabetes are already at high risk for cardiovascular disease, it is important that any potential cardiotoxicity of rosiglitazone be reported. Meta-analyses suggest that rosiglitazone, used in the treatment of type 2 diabetes, may increase the risk of myocardial infarction and death from cardiovascular causes. This interim analysis of an ongoing noninferiority trial of rosiglitazone is inconclusive but does not exclude cardiotoxicity. For patients with type 2 diabetes, cardiovascular disease is the leading cause of death and the major cause of morbidity. 1 In such patients, cardiovascular risk is considerably elevated, 2 although recent reports have moderated this concern. 3 , 4 Factors that are implicated in the development of atherosclerosis include dyslipidemia, obesity, hypertension, hyperglycemia, and hyperinsulinemia. 5 Type 2 diabetes is a progressive disease and its prevalence in the population is increasing. Since there is greater attention to glycemic targets, more patients are receiving combination therapies. Clinical trials comparing monotherapies are common, but comparisons of new dual-agent combinations with the standard of metformin plus sulfonylurea . . .